Key terms
About ACCD
Accolade, Inc. engages in the provision of technology-enabled health and benefits solutions. The company was founded by Thomas K. Spann, J. Michael Cline, and Sudhir Steven Singh in January 2007 and is headquartered in Seattle, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACCD news
Mar 19
9:04am ET
Accolade promotes Kelsi McDonald Harris to Chief People Officer
Feb 27
5:59am ET
Balancing Potential and Prudence: A Hold Rating for Accolade’s Market Prospects and Financial Strategy
Feb 26
8:25am ET
D.A. Davidson Remains a Hold on Accolade (ACCD)
Feb 26
6:44am ET
Accolade initiated with an Outperform at Leerink
Feb 06
7:48am ET
Stifel Nicolaus Sticks to Their Buy Rating for Accolade (ACCD)
Jan 22
1:45pm ET
Buy Rating on Accolade (ACCD) Backed by Strong Sales and Strategic Growth Initiatives
Jan 17
6:54am ET
Accolade price target raised to $12 from $10 at Jefferies
Jan 16
4:14pm ET
Accolade assumed with Neutral from Buy at DA Davidson
Jan 10
7:18am ET
Accolade’s Strong Fiscal Performance Tempered by Valuation Concerns: A Hold Rating Perspective
Jan 10
1:00am ET
A New Cause for Concern: Accolade, Inc. Adds a New Regulation Risk
Jan 09
7:50am ET
Accolade’s Strong Financial Outlook Prompts Buy Rating Amidst Revenue Growth and EBITDA Margin Expansion
Jan 09
7:45am ET
Accolade price target raised to $16 from $15 at Truist
Jan 09
7:36am ET
Accolade (ACCD) Receives a Buy from Stifel Nicolaus
Jan 09
7:27am ET
Accolade price target raised to $15 from $12 at Piper Sandler
Jan 09
7:17am ET
Maintaining Hold on Accolade: Balancing Positive Trends with Market Uncertainties
Jan 09
7:08am ET
Accolade price target raised to $12 from $10 at Wells Fargo
Jan 09
6:50am ET
Analysts’ Top Healthcare Picks: Accolade (ACCD), Sarepta Therapeutics (SRPT)
Jan 09
6:20am ET
Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Accolade (ACCD)
Jan 08
4:12pm ET
Accolade backs FY25 revenue view up 20%, consensus $493.01M
Jan 08
4:11pm ET
Accolade raises FY24 revenue view to $411M-$415M from $410M-$414M
Jan 08
4:07pm ET
Accolade Q4 revenue $121.5M-$125.5M, consensus $126.33M
Jan 08
4:06pm ET
Accolade reports Q3 EPS (28c), consensus (44c)
Jan 07
9:26pm ET
Truist Financial Keeps Their Buy Rating on Accolade (ACCD)
Jan 07
5:28am ET
Accolade (ACCD) Gets a Hold from BTIG
Jan 04
7:08am ET
Accolade price target lowered to $15 from $17 at Stifel
Jan 02
4:45pm ET
Accolade initiated with an Equal Weight at Barclays
Jan 02
9:11am ET
BTIG Keeps Their Hold Rating on Accolade (ACCD)
Jan 02
8:03am ET
Accolade named 2024 Digital Health Top Pick, added to Conviction List at Needham
Jan 02
6:20am ET
Analysts Conflicted on These Healthcare Names: Oramed Pharm (ORMP), Accolade (ACCD) and Milestone Pharmaceuticals (MIST)
Dec 31
5:08am ET
Accolade (ACCD) Receives a Hold from BTIG
Dec 27
5:35am ET
Accolade (ACCD): A Cautious Hold Amid Short-Term Strength and Long-Term Uncertainties
No recent news articles are available for ACCD
No recent press releases are available for ACCD
ACCD Financials
Key terms
Ad Feedback
ACCD Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACCD Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range